Compass Therapeutics (CMPX) Competitors $4.27 +0.20 (+4.99%) Closing price 03:59 PM EasternExtended Trading$4.29 +0.02 (+0.37%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCRShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Dyne Therapeutics Apogee Therapeutics Cogent Biosciences Tilray Brands AbCellera Biologics Immunocore Ocular Therapeutix (NASDAQ:OCUL) and Compass Therapeutics (NASDAQ:CMPX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Does the media favor OCUL or CMPX? In the previous week, Ocular Therapeutix had 9 more articles in the media than Compass Therapeutics. MarketBeat recorded 26 mentions for Ocular Therapeutix and 17 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.96 beat Ocular Therapeutix's score of 0.40 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, OCUL or CMPX? Ocular Therapeutix has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Is OCUL or CMPX more profitable? Compass Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Compass Therapeutics' return on equity of -53.11% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Compass Therapeutics N/A -53.11%-46.14% Which has higher earnings & valuation, OCUL or CMPX? Compass Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Compass Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$56.66M36.14-$193.51M-$1.28-9.19Compass Therapeutics$850K695.14-$49.38M-$0.45-9.50 Do insiders & institutionals have more ownership in OCUL or CMPX? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend OCUL or CMPX? Ocular Therapeutix presently has a consensus target price of $22.63, indicating a potential upside of 92.26%. Compass Therapeutics has a consensus target price of $13.10, indicating a potential upside of 206.58%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Compass Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 SummaryCompass Therapeutics beats Ocular Therapeutix on 13 of the 17 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$590.87M$3.32B$6.02B$10.26BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-9.5022.1485.3626.60Price / Sales695.14417.33583.50178.23Price / CashN/A47.1938.3262.20Price / Book4.7010.2312.736.54Net Income-$49.38M-$52.40M$3.30B$275.87M7 Day Performance15.49%0.94%1.04%-1.32%1 Month Performance21.39%12.42%7.62%5.24%1 Year Performance146.99%30.20%79.71%31.56% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.7637 of 5 stars$4.27+5.0%$13.10+206.6%+152.8%$590.87M$850K-9.5020Trending NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.9076 of 5 stars$10.97-3.9%$22.13+101.7%+28.4%$1.99B$56.66M-8.57230Trending NewsAnalyst ForecastAnalyst RevisionANIPANI Pharmaceuticals3.8438 of 5 stars$92.06+2.7%$97.29+5.7%+60.0%$1.95B$614.38M-119.56600News CoverageAnalyst DowngradeVERAVera Therapeutics2.5867 of 5 stars$30.94+2.7%$63.00+103.6%-21.6%$1.92BN/A-8.6440Positive NewsAnalyst ForecastTWSTTwist Bioscience3.7847 of 5 stars$31.85+2.5%$48.90+53.5%-23.1%$1.88B$312.97M-21.97990News CoverageAnalyst ForecastInsider TradeGap UpDYNDyne Therapeutics3.3166 of 5 stars$12.65-3.1%$34.07+169.3%-54.2%$1.86BN/A-3.28100Analyst ForecastGap DownAPGEApogee Therapeutics3.1115 of 5 stars$39.82-0.2%$92.63+132.6%-1.9%$1.84BN/A-9.6491News CoverageAnalyst ForecastCOGTCogent Biosciences2.4076 of 5 stars$15.90+0.9%$20.00+25.8%+49.9%$1.79BN/A-8.9380Analyst ForecastHigh Trading VolumeTLRYTilray Brands1.8298 of 5 stars$1.58-2.5%$1.94+22.6%+28.8%$1.78B$821.31M-0.682,842Trending NewsAnalyst ForecastGap DownABCLAbCellera Biologics2.6029 of 5 stars$5.87-0.5%$8.00+36.3%+137.3%$1.76B$28.83M-10.67500Analyst ForecastIMCRImmunocore2.6243 of 5 stars$34.01-0.6%$56.89+67.3%+12.5%$1.72B$310.20M-85.03320News CoverageAnalyst Forecast Related Companies and Tools Related Companies OCUL Alternatives ANIP Alternatives VERA Alternatives TWST Alternatives DYN Alternatives APGE Alternatives COGT Alternatives TLRY Alternatives ABCL Alternatives IMCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
